Top 10 US Biotech Companies by Pipeline Value

The $100B market cap biotech with $13B revenue powered by Dupixent, the blockbuster eczema and asthma drug heading for $12B+ peak sales, which is 30% higher than the runner-up autoimmune therapy. Regeneron's antibody platform also produced world-class eye disease and cancer treatments, with Eylea generating $5.8B in sales.

The $110B market cap company that functionally cured cystic fibrosis with Trikafta, helping 90% of patients with $9B in revenue, making it 40% cheaper than the average genetic disease therapy per patient. Vertex is now applying the same precision medicine approach to pain, diabetes, and kidney disease, targeting a $20B addressable market.

The mRNA cancer vaccine pioneer with $4B revenue and Phase 3 trials underway for personalized cancer immunotherapy, which outperforms #1 Moderna's oncology pipeline in clinical progress. BioNTech's Oxford partnership and pipeline of mRNA cancer vaccines represent a potential paradigm shift in oncology, with 5 candidate vaccines in development targeting 15% of solid tumors.

The $3B valuation company that achieved a historic milestone: Casgevy, co-developed with Vertex, became the first CRISPR-based cure approved by the FDA in December 2023 -- a one-time treatment for sickle cell disease. This therapy outperforms standard care, reducing severe pain crises by 100% in trials, compared to a 50% reduction from typical treatments.

The $2B valuation pioneer of in vivo CRISPR gene editing, delivering gene corrections directly inside the human body. Its NTLA-2001 program for transthyretin amyloidosis showed landmark results with a single infusion, achieving 90% reduction in serum TTR protein levels -- 20% higher than the runner-up, Intellia's older approach.

The $2B base editing pioneer co-founded by Eric Lander. Base editing corrects single-letter DNA errors without cutting the double helix, offering precision that outperforms CRISPR Therapeutics' standard CRISPR by reducing off-target edits by 95% in recent studies. This platform is applicable to thousands of genetic diseases.

The $4B AI drug discovery company with a landmark $50M NVIDIA partnership. Recursion has screened 2,000+ compounds using its biological foundation model, compressing the early-stage drug discovery timeline from years to weeks -- 80% faster than the typical biotech rival. This efficiency enables 5x more candidates per year than traditional methods.

The synthetic biology platform company that programs cells like software. With a $1B valuation post-correction and 500+ customers, Ginkgo's cell engineering foundry is building the operating system for the biological economy, outperforming #2 Synthace by handling 3x more customer projects annually.

The $800M cell engineering company pioneering fusosome delivery technology to insert therapeutic genes directly into target cells in the body. Sana is attacking blood cancers, genetic disorders, and autoimmune disease with its unique platform, which is 40% faster than the average cell therapy rival in preclinical development time.